MP09-02 EFFECTS OF TADALAFIL ON STORAGE AND VOIDING FUNCTION IN PATIENTS WITH MALE LOWER URINARY TRACT SYMPTOMS INCLUDING BENIGN PROSTATIC ENLARGEMENT, BASED ON A URODYNAMIC STUDY

Abstract

You have accessJournal of UrologyBenign Prostatic Hyperplasia: Medical & Non-surgical Therapy1 Apr 2017MP09-02 EFFECTS OF TADALAFIL ON STORAGE AND VOIDING FUNCTION IN PATIENTS WITH MALE LOWER URINARY TRACT SYMPTOMS INCLUDING BENIGN PROSTATIC ENLARGEMENT, BASED ON A URODYNAMIC STUDY Yoshihisa Matsukawa, Shohei Ishida, Kazuna Matsuo, Yudai Miyata, Hideo Narita, and Momokazu Gotoh Yoshihisa MatsukawaYoshihisa Matsukawa More articles by this author , Shohei IshidaShohei Ishida More articles by this author , Kazuna MatsuoKazuna Matsuo More articles by this author , Yudai MiyataYudai Miyata More articles by this author , Hideo NaritaHideo Narita More articles by this author , and Momokazu GotohMomokazu Gotoh More articles by this author View All Author Informationhttps://doi.org/10.1016/j.juro.2017.02.310AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookTwitterLinked InEmail INTRODUCTION AND OBJECTIVES Current guidelines for the treatment of benign prostatic enlargement (BPE) in several countries recommend the use of α1-blockers or PDE5 inhibitors as first treatment for male lower urinary tract symptoms (LUTS) with BPE. Tadalafil is one of the PDE5 inhibitors, and was reported to have prominent beneficial effects on subjects in some studies. However, to the best of our knowledge, the objective effects of this drug on storage and voiding function based on a urodynamic study (UDS) have not yet been reported. In this study, we investigated the effects of tadalafil on storage function and bladder outlet obstruction (BOO) based on a UDS in patients with LUTS due to BPE. METHODS This open-label, single-center prospective study recruited 65 outpatients with untreated BPE. The patients received tadalafil 5 mg a day for 12 weeks. Before and 12 weeks after drug administration, International Prostate Symptom Score (IPSS), IPSS-quality of life (QOL), and Overactive Bladder Symptom Score (OABSS) were used for assessing subjective symptoms. To evaluate storage function, first desire to void (FDV), maximum cystometric capacity (MCC), and the incidence of detrusor overactivity (DO) were measured, while the maximum flow rate (Qmax), detrusor pressure at Qmax (PdetQmax), post-void residual urine (PVR), and BOO index (BOOI) were assessed as parameters of voiding function. RESULTS A total of 60 patients with a mean age of 70.1 years and mean prostate volume of 46.7 mL were included in the analysis. Subjective symptom parameters such as IPSS, IPSS-QOL, and OABSS improved significantly at 12 weeks after treatment. In the storage phase of UDS, FDV and MCC significantly increased. Besides, out of 33 patients with DO before administration of tadalafil, 14 (42.4%) patients showed apparent improvement in DO after administration. In the voiding phase, the mean Qmax significantly increased from 7.1 to 9.0 mL/s. The mean BOOI significantly decreased from 61.6 to 47.7. CONCLUSIONS Tadalafil was effective for relieving LUTS by improving storage and voiding function as well as subjective symptoms in patients with BPE. © 2017FiguresReferencesRelatedDetails Volume 197Issue 4SApril 2017Page: e99-e100 Advertisement Copyright & Permissions© 2017MetricsAuthor Information Yoshihisa Matsukawa More articles by this author Shohei Ishida More articles by this author Kazuna Matsuo More articles by this author Yudai Miyata More articles by this author Hideo Narita More articles by this author Momokazu Gotoh More articles by this author Expand All Advertisement Advertisement PDF downloadLoading ...